Treatment of Hodgkin's lymphomas in adolescent and young adults
https://doi.org/10.17650/1818-8346-2008-0-1-2-18-26
Abstract
Clinical efficacy of DAL-HD-90m protocol in the treatment of adolescent and young patients with Hodgkin's lymphomas was analyzed. From November 1997 to April 2007, 97 patients (38 males and 59 females) aged from 15 to 45 years with first diagnosed Hodgkin's lymphomas were enrolled to trial. Patients with IA, IB and IIA stages (therapeutic group (TG) 1) were treated by 2 cycles of ODPA regimen (vincristine, procarbasine, prednisolone, adriamycin) for females and 2 cycles of OEPA regimen (vincristine, ethoposide, prednisolone, adriamycin) for males. Patients with IIB, IIIA, IE A, IE B, IIE A stages (TG 2) received additional two cycles of multi-agent chemotherapy with COPD regimen (cyclophosphamide, vincristine, prednisolone, adriamycin). Patients of TG 3 (stages IIIB, IVA, IVB, IIE B, IIIE A, IIIE B) were treated with 2 cycles of ODPA and 4 cycles of COPD regimens irrespective of the patient's sex. Radiotherapy was carried out to all patients: targets included regional lymph nodes (total local dose of 30 Gy) and additionally the residual tumor (total dose of 6-10 Gy). Complete response was achieved in 91 % patients from TG 1, 94% patients from TG 2 and 89% from TG 3 group. Six-year overall survival was 0,91±0,09; 0,88±0,08 and 0,76±0,08, respectively. The absence of CR/CRu after 2 courses of OPPA/OEPA (0,60 versus 0,93; p=0,006), initial tumors of larger volumes than 50 cm3 (0,66 versus 0,91, p=0,017) and the International Prognostic Index no lower than 4 points (0,44 versus 0,82; p=0,039) were unfavorable prognostic factors for TG3 patients in this study.
About the Authors
S. V. Semochkin
Federal State Enterprise «Federal Research Clinical Center of Pediatric Hematology, Oncology and Immunology of Russian Public Health
Russian Federation
Russian Federation
Moscow
S. S. Loriya
Federal State Enterprise «Federal Research Clinical Center of Pediatric Hematology, Oncology and Immunology of Russian Public Health
Russian Federation
Russian Federation
Moscow
A. G. Rumyantzev
Federal State Enterprise «Federal Research Clinical Center of Pediatric Hematology, Oncology and Immunology of Russian Public Health
Russian Federation
Russian Federation
Moscow
V. M. Sotnikov
Federal State Enterprise «Russian Research Center of Roentgen-Radiology» of Russian Medical Technologies
Russian Federation
Russian Federation
Moscow
References
1. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и странах СНГ в 2004 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3, прил 1):45—77.
2. Bleyer A., O'Leary M., Barr R., Ries L.A.G. Cancer Epidemiology in Older Adolescent and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975—2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.
3. Meyer R.M., Ambinder R.F., Stroobants S. Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice. Education book of American Society of Hematology 2004:184—202.
4. Hehn S.T., Miller T.P. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP? Curr Hematol Rep 2004;3(1):17—26.
5. Канаев С.В., Малинин А.П., Гершанович М.Л. Лимфогранулематоз. В кн.: Лучевая терапия злокачественных опухолей. Под. ред. Е.С. Киселевой. М., Медицина; 1996. с. 370—406.
6. Sieniawski M., Franklin J., Nogova L. et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007;25(15):2000—5.
7. Donaldson S.S., Link M.P. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 1987;5(5):742—9.
8. Schellong G., PЪtter R., BrКmswing J. et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17(12):3736—44.
9. Schellong G., Riepenhausen M. Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming postsplenectomy infections and secondary malignancies. Klin Padiatr 2004;216(6):364—9.
10. Reinders J.G., Heijmen B.J., Olofsen-van Acht M.J. et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term followup. Radiother Oncol 1999;51:35—42.
11. Yung L., Smith P., Hancock B.W. et al. Long term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults. Leuk Lymphoma 2004;45:1579—85.
12. Семочкин С.В. Оптимизация технологий лечения лимфопролиферативных заболеваний у подростков и лиц молодого возраста. Автореф. дисс. … докт. мед. наук. М.; 2007.
13. Самочатова Е.В., Владимирская Е.Б., Жесткова Н.М. и др. Болезнь Ходжкина у детей. Руководство для врачей. М., Алтус; 1997.
14. Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348(24):2386—95.
15. Dieckmann K., PЪtter R., Hofmann J. et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German- Austrian Pediatric Multicenter Trial DALHD-90. Int J Radiat Oncol Biol Phys 2003;56:644—52.
16. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339(21):1506—14.
17. Engert A., Klimm B., Josting A., Diehl V. Treatment of relapsed and refractory Hodgkin's lymphoma. Hematology (EHA Education Program) 2005;1(1):182—5.
18. Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях. М., Гэотар-мед; 2001.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457—81.
20. Diehl V., Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies. Ann Oncol 2007;18(Suppl 9):71—9.
21. Thomas J., FermО C., Noordijk E.M. et al. Results of the EORTC-GELA H9 randomized trials: the H9-F trials (comparing 3 radiation dose levels) and H9-U trials (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). Haematologica/the hematology journal 2007;92(s5):27.
22. Даценко П.В., Паньшин Г.А., Сотников В.М. и др. Новые программы комбинированного лечения лимфомы Ходжкина. Онкогематология 2007;(4):27—35.
23. Hutchinson R.J., Fryer C.J., Davis P.C. et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998;16(3):897—906.
24. Spaepen K., Stroobants S., Dupont P. et al. Can positron emission tomography with [18F]-fluorodeoxyglucose after firstline treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272—8.
Review
For citations:
Semochkin S.V., Loriya S.S., Rumyantzev A.G., Sotnikov V.M. Treatment of Hodgkin's lymphomas in adolescent and young adults. Oncohematology. 2008;(1-2):18-26. (In Russ.) https://doi.org/10.17650/1818-8346-2008-0-1-2-18-26
Views:
263
Email this article 